Background:To evaluate the efficacy and safety of donepezil and ginkgo biloba for Alzheimer5s disease.Methods:A systematic literature retrieval was carried out for eligible studies in PubMed,Embase,Cochrane Library,We...Background:To evaluate the efficacy and safety of donepezil and ginkgo biloba for Alzheimer5s disease.Methods:A systematic literature retrieval was carried out for eligible studies in PubMed,Embase,Cochrane Library,Web of Science,China National Knowledge Infrastructure,Wanfang and China Science and Technology Journal Database from the establishment of database to 1 February 2020.Nine randomized controlled trials were included in our study in the Review Manager 5.3.Results:Our meta-analysis found that compared with donepezil alone,ginkgo biloba and donepezil could improve clinical efficacy and enhance cognitive function measured by the mini-mental state examination score.No significant difference in the total adverse reaction,the digestive symptoms and the neurological symptoms between two groups was observed.Conclusion:The combination of donepezil plus ginkgo biloba could provide more benefits for Alzheimer 5s disease patients than donepezil alone.展开更多
Objectives： To explore the protective effects of Tongmai Yizhi Decoction（通脉益智汤, TYD）, a Chinese herb complex prescription against the impairment of cognitive functions and memory loss in amyloid beta 1–40（A...Objectives： To explore the protective effects of Tongmai Yizhi Decoction（通脉益智汤, TYD）, a Chinese herb complex prescription against the impairment of cognitive functions and memory loss in amyloid beta 1–40（Aβ1-40） peptide and ibotenic（IBO）-induced Alzheimer＇s disease（AD） model rats. Methods： The in vivo model was established by injecting Aβ1-40 and IBO into left hippocampal CA1 area of Sprague-Dawley（SD） rat to mimic AD. Totally 32 SD rats were divided into 4 groups, including sham operation group, AD model group, TYD group [AD rats treated with TYD at the dosage of 19.44 g/（kg·d） for 4 weeks] and huperzine A group [AD rats treated with huperzine A at the dosage of 40.5 μg/（kg·d） for 4 weeks]. Spatial learning and memory level was detected by Morris Water Maze test. Histological morphology in the hippocampus was tested by hematoxylin-eosin（HE） staining. Cyclin-dependent kinase-5（Cdk5） protein and gene expression level were investigated by Western blot analysis and real-time quantitative polymerase chain reaction（RT-q PCR）, respectively. Results： Aβ1-40 and IBO treatment induced longer escape latency of rats, compared with sham operation group from day 25（P〈0.01）. However, TYD and huperzine A obviously shortened the escape latency from day 26（P〈0.01）. Moreover, the effect of TYD was similar to huperzine A（P〉0.05）. Furthermore, HE staining also showed that TYD and huperzine A reversed the neuropathological changes in the hippocampus triggered by Aβ1-40 and IBO. TYD and huperzine A effectively reduced the expression levels of Cdk5 protein and gene located in rat hippocampus, compared with the AD model group（P〈0.01）. Conclusion： TYD could be a promising neuroprotective agent for protecting neuron from AD injury through inhibiting Cdk5 expression.展开更多
基金supported by the Scientific Research Project of Tianjin Education Commission,China(No.2018KJ031)National Natural Science Foundation of China(No.81704004).
文摘Background:To evaluate the efficacy and safety of donepezil and ginkgo biloba for Alzheimer5s disease.Methods:A systematic literature retrieval was carried out for eligible studies in PubMed,Embase,Cochrane Library,Web of Science,China National Knowledge Infrastructure,Wanfang and China Science and Technology Journal Database from the establishment of database to 1 February 2020.Nine randomized controlled trials were included in our study in the Review Manager 5.3.Results:Our meta-analysis found that compared with donepezil alone,ginkgo biloba and donepezil could improve clinical efficacy and enhance cognitive function measured by the mini-mental state examination score.No significant difference in the total adverse reaction,the digestive symptoms and the neurological symptoms between two groups was observed.Conclusion:The combination of donepezil plus ginkgo biloba could provide more benefits for Alzheimer 5s disease patients than donepezil alone.
文摘Objectives： To explore the protective effects of Tongmai Yizhi Decoction（通脉益智汤, TYD）, a Chinese herb complex prescription against the impairment of cognitive functions and memory loss in amyloid beta 1–40（Aβ1-40） peptide and ibotenic（IBO）-induced Alzheimer＇s disease（AD） model rats. Methods： The in vivo model was established by injecting Aβ1-40 and IBO into left hippocampal CA1 area of Sprague-Dawley（SD） rat to mimic AD. Totally 32 SD rats were divided into 4 groups, including sham operation group, AD model group, TYD group [AD rats treated with TYD at the dosage of 19.44 g/（kg·d） for 4 weeks] and huperzine A group [AD rats treated with huperzine A at the dosage of 40.5 μg/（kg·d） for 4 weeks]. Spatial learning and memory level was detected by Morris Water Maze test. Histological morphology in the hippocampus was tested by hematoxylin-eosin（HE） staining. Cyclin-dependent kinase-5（Cdk5） protein and gene expression level were investigated by Western blot analysis and real-time quantitative polymerase chain reaction（RT-q PCR）, respectively. Results： Aβ1-40 and IBO treatment induced longer escape latency of rats, compared with sham operation group from day 25（P〈0.01）. However, TYD and huperzine A obviously shortened the escape latency from day 26（P〈0.01）. Moreover, the effect of TYD was similar to huperzine A（P〉0.05）. Furthermore, HE staining also showed that TYD and huperzine A reversed the neuropathological changes in the hippocampus triggered by Aβ1-40 and IBO. TYD and huperzine A effectively reduced the expression levels of Cdk5 protein and gene located in rat hippocampus, compared with the AD model group（P〈0.01）. Conclusion： TYD could be a promising neuroprotective agent for protecting neuron from AD injury through inhibiting Cdk5 expression.
